No Data
No Data
Cofco Biotechnology: Half-year report for the year 2024.
Cofco Biotechnology: Summary of Half-Year Report in 2024.
Cofco Biotechnology (000930.SZ): The net income in the first half of the year was 61.4817 million yuan, reversing the loss from the same period last year.
Cofco Biotechnology (000930.SZ) announced its interim report for the first half of 2024, with revenue of 9.911 billion yuan, a year-on-year growth of 6.45%; net income attributable to shareholders of the listed company was 61.4817 million yuan, turning losses into profits year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 18.6054 million yuan; basic earnings per share was 0.0331 yuan.
Further Weakness as COFCO Biotechnology (SZSE:000930) Drops 5.3% This Week, Taking Three-year Losses to 41%
Cofco Biotechnology (000930.SZ): The main products of its subsidiary, Zhongliang Tianke Biotechnology, include natural VE series, plant sterol series, nutritional health products, and fatty acid methyl esters.
Cofco Biotechnology (000930.SZ) stated on its investor interaction platform on August 13 that its subsidiary, Tianjin Zhonghe Biotechnology Engineering Co., Ltd., specializes in natural VE series, plant sterol series, nutrition and health products, fatty acid methyl esters, etc.
COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt
No Data
No Data